INCYTE BIOSCIENCES INTERNATIONAL SÀRL
SALES AND DELIVERY TERMS AND CONDITIONS – version 10.2026
1. Scope and precedence
1.1 These Sales and Delivery Terms and Conditions (T&Cs) apply to all sales of medicinal products and related goods (Products) by Incyte Biosciences International SA, with registered office in Morges, Switzerland (Incyte), to customers with delivery address in Switzerland and the Principality of Liechtenstein.
1.2 By placing an order, the customer accepts these T&Cs. Any customer terms (including purchase conditions) are excluded unless expressly accepted by Incyte in writing. This “battle of forms” exclusion is standard in Swiss pharma sales AGBs.
2. Orders and acceptance
2.1 Orders are binding upon written confirmation by Incyte or its logistics partner or upon dispatch. Incyte may refuse orders (e.g., compliance, supply constraints, distribution set-up).
2.2 Partial deliveries are permitted where reasonable.
3. Prices, taxes and invoicing
3.1 Prices are those valid on the date of delivery/dispatch, plus applicable VAT and statutory charges. Price lists are non-binding and may change without prior notice.
3.2 Unless agreed otherwise, invoices are issued electronically.
4. Logistics, Distribution and Invoicing
4.1 Order processing, warehousing, distribution, transport coordination and invoicing are handled on behalf of Incyte by Alloga AG (or any successor logistics partner appointed by Incyte).
4.2 Deliveries are made ex warehouse Alloga AG.
4.3 Invoices may be issued by Alloga AG in the name and on behalf of Incyte. Payment to the bank account indicated on the invoice discharges the customer’s obligation toward Incyte.
4.4 Returns, where authorised, must be executed strictly in accordance with the instructions of Alloga AG.
5. Payment
5.1 Payment term: net 30 days from invoice date, without deduction.
5.2 Set-off is excluded unless mandatory by law. Late payment may trigger default interest and collection costs.
6. Delivery, risk and GDP
6.1 Delivery dates are indicative unless expressly agreed as fixed in writing. Supply shortages or delays do not entitle the customer to penalties or damages to the extent permitted by law.
6.2 Risk transfers to the customer upon handover to the carrier or at delivery (as specified in the order confirmation).
6.3 Products must be transported, stored and handled in accordance with Good Distribution Practice (GDP).
7. Inspection, complaints and wrong delivery
7.1 The customer must inspect Products immediately upon receipt. Obvious defects, transport damage, shortages or wrong deliveries must be notified to Incyte in writing without delay and no later than 5 working days after receipt; otherwise, delivery is deemed accepted.
7.2 Hidden defects must be notified in writing immediately after discovery.
7.3 Incyte may request batch/lot numbers, quantities, photos, temperature logs (where applicable) and any other documentation reasonably required to assess the complaint.
8. Returns policy
8.1 No returns for stock management: Products that are expired, approaching expiry, surplus, or no longer needed are not eligible for return, credit or replacement (unless explicit guidance is provided by Incyte).
8.2 Returns are accepted only if: (i) Incyte confirms in writing that a return is authorized, (ii) the Products relate to a confirmed wrong delivery attributable to Incyte or a quality/safety issue, and (iii) return instructions are followed.
8.3 Any authorized return must comply with GDP and must be in original, unopened, undamaged packaging with intact tamper evidence and full traceability. Cold-chain products may be excluded from return unless Incyte expressly agrees in writing.
8.4 Title to returned Products transfers to Incyte upon receipt at the designated return location.
9. Product recalls and safety actions
9.1 In case of an official recall or safety action, Incyte will provide specific written instructions (return, quarantine, destruction, documentation) and the applicable timelines.
10. Liability
10.1 To the extent permitted by law, Incyte’s liability is limited to direct damages and excludes indirect or consequential losses (e.g., lost profit, business interruption).
10.2 Nothing limits liability for intent or gross negligence where mandatory.
11. Title retention
11.1 Products remain Incyte’s property until full payment has been received.
12. Compliance
12.1 The customer shall comply with applicable laws and regulations (including therapeutic products rules, GDP/GSP requirements, anti-corruption and sanctions/export controls). The customer must ensure Products are dispensed/handled only as permitted and in original packaging.
13. Governing law and jurisdiction
13.1 These T&Cs and all contracts under them are governed by Swiss substantive law, excluding its conflict of laws rules and the CISG.
13.2 Exclusive place of jurisdiction is Lausanne, Canton of Vaud, Switzerland (or another Vaud venue specified by Incyte in the order confirmation), subject to mandatory legal venues.